期刊文献+

乳腺癌预后危险因素分析 被引量:3

The analysis of risk factors influencing prognosis of breast cancer
下载PDF
导出
摘要 目的探讨影响乳腺癌患者预后情况的高危因素,为制定有效的临床治疗方案奠定理论基础。方法对162例乳腺癌病例进行调查分析,采用Cox回归对所获得资料进行统计分析。结果不恰当的激素治疗可能是乳腺癌预后的危险因素,而雌激素受体和孕激素受体则具有保护作用。结论乳腺癌激素治疗的不恰当对乳腺癌的复发及转移有促进作用,在临床治疗方面尤其值得注意。 Objective To analyze the risk factors which influence the prognosis of breast cancer, to investigate the treatment strategy of breast cancer in clinical. Methods 162 cases of breast cancer were analyzed by the single factor and the multi factors Cox regression analysis. Results Multi factors Cox regression analysis results indicated that the incorrect endocrine therapy may be risk factor which affected the patient’s prognosis of breast cancer. Hormone receptor status,extrogen receptor and extrogen receptor influenced the prognosis of breast cancer,and hormone receptor-positive group was better than that of the receptor-negative group. Conclusion The incorrect endocrine therapy may take part in the metastasis and recurrence of breast cancer.
作者 陈熙昀 谢芳
出处 《中国现代医药杂志》 2013年第6期1-4,共4页 Modern Medicine Journal of China
基金 "莙政学者"研修计划及国家自然科学基金资助项目(编号:30672390)
关键词 乳腺癌 雌激素受体(ER) 孕激素受体(PR) 激素治疗 预后 Breast cancer Estrogen receptor Progestogen receptor Endocrine therapy Prognosis
  • 相关文献

参考文献12

  • 1Boeker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol ,2002,86: 116-119. 被引量:1
  • 2Shao C, Folkard M, Held KD, et al. Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer,2008,30,8:184. 被引量:1
  • 3Noguchi S,Motomura K,Inaji H,et al. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer, 1993 ,71 (4) :1266-1272. 被引量:1
  • 4Cohen I, Shapira J , Beyth Y, et al. Estrogen and progesterone re?ceptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest, 1998,45 (2) :126- 131. 被引量:1
  • 5Kiyoto S, Hara F , Osumi S, et al. A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy. Gan To Kagaku Ryoho,2009,36(13) :2623-2625. 被引量:1
  • 6Yu KD, Liu GY, Di GH, et al. Progesterone receptor status pro?vides predictive value for adjuvant endocrine therapy in older es?trogen receptor -positive breast cancer patients. Breast, 2007 , 16 (3) :307-315. 被引量:1
  • 7Liang Y, Hou M, Kallab AM, et al. Induction of anti proliferation and apoptosis in estrogen receptor negative MDA -231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen com?bination therapy-a role for TGFbetal. Int J Oncol,2003,23(2): 369-380. 被引量:1
  • 8Yu KD, Di GH, W u J, et al. Breast cancer patients with estrogen receptomegative I progesterone receptor - positive tumors: being younger and getting less benefit from adjuvant tamoxifen treat?ment. J Cancer Res Clin Oncol,2008, 134(12) :1347-1354. 被引量:1
  • 9Zhou Y, Yau C, Gray JW , et al. Enhanced NF kappa B and AP-l transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 2007,7: 59. 被引量:1
  • 10Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol Cell Bioi, 1997,17 (3) :1274-1280. 被引量:1

同被引文献45

  • 1Kaufmann M,Von Minckwitz G, Mamounas E, et al. Rec- ommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant SystemicTherapy in Primary Breast Cancer[J]. Annals of surgical oncology,2012,19(5) ..1508-1516. 被引量:1
  • 2Pogue.-Geile KL, Kim C, JeongJ H, et al. Predicting De- gree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31 [J]. Journal of the National Cancer Institu- te,2013,105(23) ..1782-1788. 被引量:1
  • 3Guarneri V,Broglio K,Kau S,et al. Prognostic value of pathologic complete response after primary chemother- apy in relation to hormone receptor status and other factors [J]. Journal of Clinical Oncology, 2006,24 (7) : 1037-1044. 被引量:1
  • 4ASlamon D,Clark G,Wong S,et al. Human breast cancer.. correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987,235 (4785) : t77- I82. 被引量:1
  • 5Baselga J, Bradbury I, Eidtmann H, et al. , Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO) : a randoraised, open-label, mul- ticentre, phase 3 trial[J]. The Lancet, 2012, 379 (9816) : 633-640. 被引量:1
  • 6Kim MM, Allen P, Gonzalez-AnguloAM, et al. Patho- logic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer[J]. Annals of Oncology,2013,24(8) : 1999-2004. 被引量:1
  • 7Jones RL, Salter J, Hern RA, et al, Relationship be- tween oestrogen receptor status and proliferation in predicting response and long-term outcome to neoad- juvant chemotherapy for breast cancer [J]. Breast cancer research and treatment, 2010, 119 (2): 315- 323. 被引量:1
  • 8李颖嘉,文戈,何洁.超声造影定量分析对乳腺良恶性肿瘤血流灌注异质性的评价[J].中华超声影像学杂志,2009,18(6):517-520. 被引量:17
  • 9张伟,赵军,陈晓东,彭大云,陈敬文,周永梅.CISH技术在乳腺癌Her-2基因检测中的应用[J].中国组织化学与细胞化学杂志,2010,19(2):206-208. 被引量:1
  • 10周林秋,虞立平,顾军.乳腺癌患者新辅助化疗疗效因素的相关性研究[J].医学研究生学报,2012,25(6):609-611. 被引量:8

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部